ResearcherPeking UniversityActive in the last 2 years
Junsheng Xue
Matched on OpenAlex author ID A5100551457. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 4
- Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1038/s41401-024-01403-8↗
- An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft. Co-author DOI 10.1038/s41401-022-00960-0↗
- Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.lfs.2020.118302↗
- N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation. Co-author DOI 10.1016/j.taap.2019.114789↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Qingyu Yao · 4 shared papers, 2019–2025 · strength 0.63
- Paper Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. DOI 10.1038/s41401-024-01403-8↗
- Paper An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancr… DOI 10.1038/s41401-022-00960-0↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Tianyan Zhou · 3 shared papers, 2019–2025 · strength 0.44
- Paper Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. DOI 10.1038/s41401-024-01403-8↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Jun Zhou · 2 shared papers, 2023–2025 · strength 0.44
- Paper Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. DOI 10.1038/s41401-024-01403-8↗
- Paper An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancr… DOI 10.1038/s41401-022-00960-0↗
- Ye Yao · 3 shared papers, 2019–2023 · strength 0.37
- Paper An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancr… DOI 10.1038/s41401-022-00960-0↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Chunyi Hao · 2 shared papers, 2019–2020 · strength 0.19
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Hong Su · 2 shared papers, 2019–2020 · strength 0.19
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Tianyan Zhou · 1 shared paper, 2023 · strength 0.18
- Can Cui · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.